The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Lupus - Lupus syndrome (see also Vd)
Publications
Overlapping drug-induced vasculitis, ANCA-associated vasculitis, and lupus nephritis caused by low-dose hydralazine.
International journal of rheumatic diseases 2023 Jul 14;; — 2023 Jul 14
The Utility of Bronchoscopy in Hydralazine-Induced ANCA-Associated Vasculitis.
Case reports in pulmonology 2023;2023;1461011 — 2023 — 1461011
An intriguing case of anemia and renal failure.
Proceedings (Baylor University. Medical Center) 2019 Jan;32;78-79 — 2019 Jan — 78-79
Successful use of rituximab for hydralazine-induced anti-neutrophil cytoplasmic antibodies-associated vasculitis.
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2019 Jan-Feb;30;226-230 — 2019 Jan-Feb — 226-230
Arnaud L, Mertz P, Gavand PE, Martin T, Chasset F, Tebacher-Alt M, Lambert A, Muller C, Sibilia J, Lebrun-Vignes B, Salem JE
Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database.
Annals of the rheumatic diseases 2019 04;78;504-508 — 2019 04 — 504-508
Hydralazine-induced lupus erythematosis.
Journal of clinical hypertension (Greenwich, Conn.) 2012 Feb;14;133-6 — 2012 Feb — 133-6
Hydralazine for essential hypertension.
The Cochrane database of systematic reviews 2011 Nov 09;;CD004934 — 2011 Nov 09 — CD004934
Drug-induced lupus erythematosus: incidence, management and prevention.
Drug safety 2011 May 01;34;357-74 — 2011 May 01 — 357-74
Do selected drugs increase the risk of lupus? A matched case-control study.
British journal of clinical pharmacology 2010 Oct;70;588-96 — 2010 Oct — 588-96
Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitis.
Modern rheumatology 2009;19;338-47 — 2009 — 338-47
Fulminating hydralazine-induced lupus pneumonitis.
Arthritis and rheumatism 2006 Jun 15;55;501-6 — 2006 Jun 15 — 501-6
Late systemic complications of hydralazine (apresoline) therapy.
Journal of the American Medical Association 1955 Mar 12;157;894-9 — 1955 Mar 12 — 894-9
Studies on the control of hypertension by hyphex. II. Toxic reactions and side effects.
Circulation 1953 Dec;8;829-39 — 1953 Dec — 829-39
Hydralazine-induced lupus and vocal fold paralysis.
The Journal of laryngology and otology 1998 Sep;112;875-7 — 1998 Sep — 875-7
Antigen specificity in hydralazine associated ANCA positive systemic vasculitis.
QJM : monthly journal of the Association of Physicians 1995 Nov;88;775-83 — 1995 Nov — 775-83
Effect of acute cytomegalovirus infection on drug-induced SLE.
Postgraduate medical journal 1994 Oct;70;738-40 — 1994 Oct — 738-40
Drug-induced lupus caused by very-low-dose hydralazine.
British journal of rheumatology 1986 May;25;225 — 1986 May — 225
Laryngeal manifestations of drug induced lupus.
The Journal of rheumatology 1987 Apr;14;375-7 — 1987 Apr — 375-7
Autoantibodies against neutrophil cytoplasm components in systemic lupus erythematosus and in hydralazine-induced lupus.
Clinical and experimental immunology 1990 Sep;81;380-3 — 1990 Sep — 380-3
Hypocomplementemia in hydralazine-associated systemic lupus erythematosus.
The American journal of medicine 1978 Sep;65;553-6 — 1978 Sep — 553-6